MARKET

URGN

URGN

Urogen Pharma
NASDAQ
28.78
-0.90
-3.03%
After Hours: 28.78 0 0.00% 16:10 05/15 EDT
OPEN
29.26
PREV CLOSE
29.68
HIGH
29.59
LOW
28.26
VOLUME
944.07K
TURNOVER
--
52 WEEK HIGH
32.37
52 WEEK LOW
3.420
MARKET CAP
1.40B
P/E (TTM)
-10.4838
1D
5D
1M
3M
1Y
5Y
1D
UroGen Pharma reports month results from UTOPIA trial
TipRanks · 1d ago
UroGen Announces That UGN-103 Achieved A 94.5% Durability Of Response At Six Months In The Ongoing Phase 3 UTOPIA Trial For Intravesical Solution In Patients With Bladder Cancer
Benzinga · 1d ago
Urogen Shows 3-Year Durability In ENVISION Trial Of ZUSDURI For Recurrent Bladder Cancer
NASDAQ · 3d ago
UroGen Pharma presents 36-month ENVISION trial data
TipRanks · 3d ago
UroGen Pharma Announces 36-Month Duration Of Response By Kaplan-Meier Estimate In Patients Who Achieved Complete Response At Three Months In Pivotal Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution.
Benzinga · 3d ago
UroGen Pharma assumed with a Buy at Ladenburg
TipRanks · 5d ago
UroGen Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 5d ago
UroGen Pharma Price Target Raised to $45.00/Share From $40.00 by HC Wainwright & Co.
Dow Jones · 5d ago
More
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Webull offers Urogen Pharma Ltd stock information, including NASDAQ: URGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, URGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading URGN stock methods without spending real money on the virtual paper trading platform.